MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Study of Sulfasalazine in Treating Painful Neuropathy

Phase 2

Terminated

Conditions: Painful Neuropathy

Interventions: Drug: placebo
Drug: Sulfasalazine

First Posted Date: 2012-08-17

Last Posted Date: 2018-08-22

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 8

Registration Number: NCT01667029

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

STA-9090 in Patients With Advanced Hepatocellular Cancer

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: STA-9090

First Posted Date: 2012-08-16

Last Posted Date: 2018-04-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 16

Registration Number: NCT01665937

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

The Metabolomics of Anaphylaxis

Withdrawn

Conditions: Patients With AERD Undergoing Aspirin Desensitization

First Posted Date: 2012-08-16

Last Posted Date: 2019-03-07

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01666275

Locations: 🇺🇸
Massachusetts General Hospital - Allergy Associates, Boston, Massachusetts, United States

The Metabolomics of Anaphylaxis to Immunotherapy

Withdrawn

Conditions: Anaphylaxis as a Result of Allergen or Venom Immunotherapy

First Posted Date: 2012-08-16

Last Posted Date: 2019-03-07

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01666288

Locations: 🇺🇸
Massachusetts General Hospital - Allergy Associates, Boston, Massachusetts, United States

Simvastatin Augmentation of Lithium Treatment in Bipolar Depression

Phase 2

Terminated

Conditions: Bipolar Disorder

Interventions: Drug: Simvastatin
Drug: Placebo

First Posted Date: 2012-08-16

Last Posted Date: 2017-05-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 4

Registration Number: NCT01665950

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Improving Diabetes Outcomes Through Lifestyle Change (IDOLc)Study

Not Applicable

Completed

Conditions: Type 2 Diabetes
Obesity

Interventions: Behavioral: Usual Care
Behavioral: Group Lifestyle Program

First Posted Date: 2012-08-16

Last Posted Date: 2015-09-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 57

Registration Number: NCT01665989

Locations: 🇺🇸
Diabetes Research Center - Massachusetts General Hospiral, Boston, Massachusetts, United States

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease

Phase 4

Completed

Conditions: Microvascular Angina

Interventions: Drug: Nebivolol

First Posted Date: 2012-08-15

Last Posted Date: 2017-04-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 12

Registration Number: NCT01665508

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Optical Frequency Domain Imaging for Non-melanoma Skin Cancers

Not Applicable

Completed

Conditions: Non-Melanoma Skin Cancer (NMSC)

Interventions: Device: OFDI

First Posted Date: 2012-08-10

Last Posted Date: 2023-03-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT01662713

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

The Effect of Calorie Deprivation on Adipose Tissue Distribution

Not Applicable

Completed

Conditions: Healthy

Interventions: Behavioral: Fasting

First Posted Date: 2012-08-07

Last Posted Date: 2017-02-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 12

Registration Number: NCT01658397

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Proton or Photon RT for Retroperitoneal Sarcomas

Phase 1

Recruiting

Conditions: Retroperitoneal Sarcoma

Interventions: Radiation: IG-IMPT
Radiation: IG IMRT

First Posted Date: 2012-08-07

Last Posted Date: 2020-09-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 80

Registration Number: NCT01659203

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy